In Wake Of Deals, Concert Is Latest To File For IPO
This article was originally published in The Pink Sheet Daily
Lexington, Mass.-based Concert became the second company studying deuterium chemistry in the current pipeline for initial public offerings. It joins Auspex, which updated its filing this week, as did pain drug developer Cara.
You may also be interested in...
The two biotech companies have teamed up to create a follow-on product to Jazz’s narcolepsy drug, a collaboration that could add to the patent-life of Xyrem and be financially beneficial for both companies.
The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.
Do high biotech share prices portend stock-heavy deal-making in lieu of all-cash transactions? Also, Biogen shares the risk with Eisai in an Alzheimer’s deal, while newly public Genocea and cell therapy specialist NeoStem both teamed with Harvard researchers.